Quantcast
Channel: BioTuesdays » Sutent
Browsing all 3 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

Top pedigree leading Xcovery’s kinase inhibitors

With two leading biotech entrepreneurs and scientists at the helm, closely held Xcovery Holdings has a leg up as it continues development of next generation kinase inhibitors as treatments for cancer...

View Article



Image may be NSFW.
Clik here to view.

Leerink starts Marati at outperform

Leerink Swann has initiated coverage of Mirati Therapeutics (NASDAQ:MRTX) with an “outperform” rating and price target of $25. The share are changing hands at $17.38 on Monday morning. Mirati is an...

View Article

Image may be NSFW.
Clik here to view.

Roth starts Argos Therapeutics at buy

Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer...

View Article
Browsing all 3 articles
Browse latest View live




Latest Images